These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 16911934

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 3. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouillères O, Carbonell N, Loria A, Poupon R.
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [Abstract] [Full Text] [Related]

  • 4. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V.
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL.
    Antivir Ther; 2009 Nov; 14(5):679-85. PubMed ID: 19704171
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H.
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [Abstract] [Full Text] [Related]

  • 8. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G, Cui Z, Wang B, Yao J, Zeng M.
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [Abstract] [Full Text] [Related]

  • 9. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H, Ma LX, Xu WS, Zhang HY, Yu LJ, Duan HY.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [Abstract] [Full Text] [Related]

  • 12. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 13. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.
    Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [Abstract] [Full Text] [Related]

  • 17. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN, Liaw YF.
    Antivir Ther; 2006 Mar; 11(7):947-52. PubMed ID: 17302259
    [Abstract] [Full Text] [Related]

  • 18. [Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B].
    Deng H, Zhao ZX, Xu QH, Zhou YP, Chen YM, Yao JL.
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):305-8. PubMed ID: 12773249
    [Abstract] [Full Text] [Related]

  • 19. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN, Liaw YF, Atkins M.
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [Abstract] [Full Text] [Related]

  • 20. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH.
    Antivir Ther; 2009 Sep; 14(2):203-10. PubMed ID: 19430095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.